Lonapegsomatropin

Limits on what this shows

• Key negative/null findings: Both trial comparisons show a real, consistent-direction shift versus an active comparator (daily somatropin) and versus placebo (adults), not merely versus baseline; no source located found lonapegsomatropin lowering phosphate or alkaline phosphatase.
• At-risk subgroups: Patients with pre-existing hyperphosphatemia or chronic kidney disease, where renal phosphate clearance is already impaired (extrapolated from the somatropin-class mechanism; not separately studied for lonapegsomatropin).

Regulatory status

SKYTROFA US PI, Section 5.14 (Laboratory Tests): "Serum levels of alkaline phosphatase and phosphate may increase after SKYTROFA therapy." Section 5.14 also notes parathyroid hormone "may increase after somatropin treatment."

Population evidence

FDA label Section 6.1, pediatric trial (the heiGHt trial cohort, lonapegsomatropin vs. daily somatropin): "More SKYTROFA-treated patients shifted from normal baseline levels to elevated phosphate and alkaline phosphatase levels at the end of the trial compared to the daily somatropin group (44.2% vs. 30.2% and 19.2% vs. 9.4%, respectively)." Section 6.1, separate adult trial (SKYTROFA vs. placebo): "More SKYTROFA-treated patients shifted from normal or low baseline levels to elevated alkaline phosphatase levels at the end of the trial compared to the placebo group (14% vs. 6%)."

Mechanism

Named, extrapolated from the identical released active moiety: GH/IGF-1 increases osteoblastic bone turnover and renal tubular phosphate reabsorption, raising serum phosphate and alkaline phosphatase as growth accelerates.

Counter-evidence held on record

No source found suggests lonapegsomatropin lowers phosphate or alkaline phosphatase. Both cited comparisons come from within the same sponsor-authored regulatory document, which is why this is graded orange rather than red despite two numerically distinct trial populations. Excess-direction finding. No phosphate supplementation is ever indicated here; monitor for hyperphosphatemia specifically in patients with renal impairment. This mirrors the identical labeled effect for daily somatropin, since the active moiety released by both drugs is the same molecule.

Limits on what this shows

• Key negative/null findings: Label states the effect is usually transient and dose dependent; no incidence percentage specific to fluid retention is broken out in the sections reviewed.
• At-risk subgroups: Adults, especially adult-onset GHD; patients with pre-existing hypertension, heart failure, or other edema-prone states (extrapolated from the somatropin-class pattern).

Regulatory status

SKYTROFA US PI, Section 5.6: "Fluid retention during somatropin therapy may occur. Clinical manifestations of fluid retention (e.g., edema, arthralgia, myalgia, nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent."

Population evidence

FDA label, Tier A, drug-specific labeling based on the SKYTROFA clinical development program. The label does not separately quantify incidence for SKYTROFA versus daily somatropin for this specific manifestation the way it does for phosphate/alkaline phosphatase.

Mechanism

Extrapolated from the somatropin class: GH stimulates the renin-angiotensin-aldosterone axis and renal epithelial sodium channel (ENaC) activity, promoting sodium and secondary water reabsorption. The SKYTROFA label itself does not name this specific mechanism for lonapegsomatropin; it is carried over from the shared active moiety.

Counter-evidence held on record

No source located suggests lonapegsomatropin causes fluid or sodium loss. This is a retention/excess risk, not a depletion. Sodium supplementation is not indicated and could worsen fluid overload. Symptomatic retention should go to the prescriber for dose review, not to independent dietary changes.

Limits on what this shows

• Key negative/null findings: Population-level data from the drug's own pivotal trials show no such effect on average: the heiGHt trial reported fasting glucose and HbA1c "generally stable over time" through week 52 (baseline HbA1c 5.05±0.32% on lonapegsomatropin vs. 5.00±0.33% on daily somatropin; fasting glucose 87-88 mg/dL in both arms at baseline and week 52), and the enliGHten 2-year trial reported HbA1c stable at approximately 5.2-5.3% through week 78. Both case reports occurred in patients with pre-existing obesity and, in one case, concurrent glucocorticoid therapy, and both patients had normal HbA1c despite extreme acute glucose elevation, indicating an acute pharmacologic insulin-resistance event rather than a chronic metabolic shift.
• At-risk subgroups: Pediatric patients with obesity, prediabetes, or concurrent glucocorticoid replacement therapy; the label's general caution about higher doses is consistent with both reported cases occurring at or near standard weight-based dosing shortly after the first injection.

Regulatory status

SKYTROFA US PI, Section 5.4: "Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. Previously undiagnosed impaired glucose tolerance and overt type 2 diabetes mellitus may be unmasked." Section 7: "Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."

Population evidence

Alkhatib, Dauber, Estrada, Majidi (2023), Horm Res Paediatr, DOI 10.1159/000530522, PMID 37015214: single pediatric case, 12-year-9-month-old boy with obesity and prediabetes; initial serum glucose 500 mg/dL (336 mg/dL after 1L normal saline) the day after the first lonapegsomatropin dose, HbA1c 5.7% (normal), urine ketones 2+, resolved by day 4 with weekly GH discontinued and daily GH resumed months later. Separate case, JCEM Case Reports 2026, DOI 10.1210/jcemcr/luag198 (accessed via the article's Oxford Academic page): 13-year-old boy with hypopituitarism, obesity (BMI 35.3 kg/m²), and concurrent hydrocortisone/levothyroxine/desmopressin; presented with frank DKA on day 4 after lonapegsomatropin (glucose 333 mg/dL, bicarbonate 6 mmol/L, venous pH 7.19, HbA1c 5.7%, markedly elevated C-peptide 26.6 ng/mL confirming preserved but resistant insulin secretion, autoimmune diabetes markers negative); resolved with insulin infusion and GH discontinuation, remained normoglycemic off GH over 2 years follow-up.

Mechanism

Named: GH/IGF-1 antagonizes insulin action and suppresses its anti-lipolytic effect, producing acute insulin resistance; both case reports proposed this as compounded by obesity and, in the second case, concurrent glucocorticoid replacement.

Counter-evidence held on record

The two pivotal registration trials (heiGHt, enliGHten) found stable average glucose and HbA1c across the treated population; the case reports describe extreme presentations in patients with additional risk factors, not a typical-patient effect. This is disclosed explicitly rather than let the rare severe cases imply a population-wide risk. Excess-direction glucose effect. Not a basis for any dietary sugar restriction claim beyond ordinary glucose monitoring; insulin or antihyperglycemic dose adjustment is a prescriber decision, especially in the first weeks of therapy in obese or glucocorticoid-treated patients.

Limits on what this shows

• Key negative/null findings: Bone-age advancement, the marker most directly tied to over-exposure risk, "advanced similarly in both groups" (0.75 vs. 0.76 bone-age/chronological-age ratio) in the heiGHt trial, suggesting the fluctuation does not translate into excess skeletal maturation relative to daily dosing at the population level.
• At-risk subgroups: Cannot be determined from the small (n=11) pharmacokinetic substudy; not established whether any subgroup experiences a clinically different fluctuation magnitude.

Regulatory status

Not separately called out as a warning in the label, though the label's pharmacodynamics section (12.2) confirms a dose-linear IGF-1 response to released somatropin.

Population evidence

Thornton et al. (2021), the Phase 3 heiGHt Trial, J Clin Endocrinol Metab, PMID 34272849, DOI 10.1210/clinem/dgab529: pharmacokinetic substudy, n=11. Peak IGF-1 SDS occurred 2-3 days post-dose, mean +1.20 (1.22) at week 39; trough occurred 6-7 days post-dose, mean -0.69 (0.98) at week 52, a within-week SDS swing of approximately 2 points. Average (time-weighted) IGF-1 SDS across the full trial population at week 52 was 0.72 (0.09) on lonapegsomatropin versus -0.02 (0.12) on daily somatropin (P<0.0001), the two dosing regimens targeting a similar average exposure through different exposure profiles.

Mechanism

Named and directly measured: once-weekly subcutaneous dosing with a roughly 25-hour half-life for released somatropin necessarily produces a rise-then-decay concentration profile across a 7-day interval, unlike daily dosing, which stays closer to steady state.

Counter-evidence held on record

No study located found the fluctuation to be clinically harmful; the same trial's bone-age data argues against a meaningful downstream growth-safety difference from daily dosing. This is a pharmacodynamic characteristic of the weekly dosing format, not a nutrient effect, and is graded yellow (context flag) rather than orange because no adverse clinical outcome has been tied to the fluctuation itself in the cited data. IGF-1 remains the standard monitoring marker for dose titration regardless.

Limits on what this shows

• Key negative/null findings: The two largest, most recent studies (combined n=208 treated children) found no change in 25(OH)D with daily rhGH treatment; no study located found any GH product lowering 25(OH)D.
• At-risk subgroups: GHD children have a high baseline prevalence of vitamin D insufficiency independent of treatment, reflecting the underlying condition rather than any GH product's pharmacology, per the confounding-by-indication rule.

Regulatory status

Not addressed in the SKYTROFA label.

Population evidence

No study of lonapegsomatropin and vitamin D was found in the searches conducted for this review. Class-level: Wei, Tanaka, Kubo, Ono, Kanzaki, Seino (1997), Eur J Endocrinol, PMID 9037126, n=12 GHD children, 6 months of daily GH: 1,25-dihydroxyvitamin D increased (P<0.05); 25-hydroxyvitamin D (the standard status marker) unchanged. Durá-Travé et al. (2020), J Endocrinol Invest, PMID 32215862, n=98 GHD children vs. 247 controls, 24 months: GH therapy "didn't modify vitamin D levels." Durá-Travé & Gallinas-Victoriano (2022), Children (Basel), PMID 35626902, n=110 GHD children vs. 377 controls, 48 months: calcidiol unchanged (P=0.501) while PTH rose steadily (P<0.001) independent of vitamin D status. Hamza, Hamed, Sallam (2018), J Investig Med, DOI 10.1136/jim-2017-000618, n=50 GHD children vs. 50 controls: 25(OH)D rose from 18.42±5.41 to 34.5±10.1 ng/mL after 1 year (P<0.001), a reverse-direction finding in tension with the two larger null studies.

Mechanism

Named: GH/IGF-1 stimulates renal 1-alpha-hydroxylase, increasing conversion of 25(OH)D to active 1,25(OH)2D, a conversion/activation effect, not a depletion of vitamin D stores. This mechanism would apply to any GH product effectively raising IGF-1, including lonapegsomatropin.

Counter-evidence held on record

The two largest controlled cohorts are themselves the counter-evidence to any depletion claim, for the shared active moiety under daily dosing; none of this is drug-specific to lonapegsomatropin. Reverse-direction or null class-level finding, not a depletion signal, and not a basis for withholding vitamin D monitoring in GHD children generally given the real, indication-linked baseline deficiency prevalence in this population.

Limits on what this shows

• Why no grade: Not applicable: this section is empty because lonapegsomatropin-specific evidence for mitochondrial burden, oxidative stress, copper, iron, gut microbiome risk, oxygen delivery/utilization, and ATP production is genuinely absent (confirmed by direct, zero-result PubMed searches for each combination, see Sources), but every one of the seven has real Tier B/C class-level supporting literature via the somatropin active moiety the prodrug releases, which is sufficient under this protocol's rules to grade yellow rather than ungraded.

What would reopen this section

A future finding that any yellow-graded class-level source turns out not to reflect the actual pharmacology of released somatropin, or a future search that could not locate even the class-level evidence currently cited, which would require re-evaluating that specific entry.